Howie Mandel turned a panic attack into NOCD, now valued near $270M in 2024

Howie Mandel’s OCD story did not start as a business plan. It started on The Howard Stern Show, when he “didn't mean to” and ended up spiraling into a panic attack over something as ordinary as opening a door, unable to get past touching the doorknob. The words came out before he could stop them, and the clip aired on Stern's show, leaving Mandel to walk out and process what had just happened on a busy New York City street. Then a stranger approached and said, “I just heard you on Stern. Me too.” Mandel told Fortune this was “the first time I connected with somebody else,” and “the first comfort I got,” after decades without language for what was happening “in here.”

That moment helped set in motion a two-decade arc that now finds Mandel as the public face of NOCD, the telehealth company focused on OCD. NOCD, last valued at nearly $270 million in 2024, currently provides at least a million therapy sessions annually and says more than 140 million people can access it through their insurance. That’s the key: this is not just influencer mental health messaging. It is a specialized care delivery model that grew from personal narrative into scaled, covered treatment. And in January, NOCD announced its acquisition of Rebound Health, a PTSD-focused platform, launching a parent brand called Noto, named after the AI-powered software that has fueled its growth.

To understand why this matters to executives, investors, and platform builders, you have to zoom in on the problem NOCD is trying to solve. The source is blunt about misdiagnosis and mismatch: Mandel says when people approach him and minimize OCD as “a little OCD” because they like things in order, he does not “let it slide,” comparing that phrasing to “a touch of that cancer.” He describes OCD as compulsions that you cannot “fucking stop,” like repeated handwashing and the time-sink that can swallow hours. In other words, OCD is not “preference.” It is a disorder with behaviors that take over your day and your choices.

The market reason specialized telehealth can scale is operational. General therapy availability is one thing. Treatment that actually matches the gold-standard intervention is another. NOCD offers specialized therapy specifically for OCD, including exposure and response prevention therapy. The source also makes the “expertise” argument directly: Mandel says if you have OCD, you need someone who is not just familiar with it but is an expert, and compares it to going to a spinal expert rather than a family doctor. NOCD says it has trained about 1,000 therapists specializing in exposure and response prevention therapy, and it recently added prolonged exposure therapy for a significant subset of users dealing with both OCD and PTSD. That last clause is important because it links two previously distinct demand pools under one treatment infrastructure.

NOCD’s growth also has a famous endorsement-shaped flywheel. Mandel is not the only celebrity tugging on this thread. Billy Bob Thornton reached out after seeing the NOCD campaign. Thornton said he grew up without understanding OCD, thinking he invented it, and that he would count to 100 five times in his head as a control ritual. Decades later, Thornton bonded with Warren Zevon after Zevon watched Thornton open and close a mailbox three times, then said, “You have it too, huh?” Thornton later came on Mandel’s podcast, Howie Mandel Does Stuff, and compared notes on “how tiring it is” to go through a day without being pulled into obsessions and compulsions.

But the real business implication is that “celebrity galore” did not arrive in a vacuum. Mandel says well-known musicians, athletes, and actors have reached out privately after seeing the ads, people who recognized themselves and wanted to talk without necessarily going public. That suggests NOCD’s campaign created demand for conversations that may have been socially suppressed or poorly labeled. For boards and operators, this is a distribution insight: when a platform clarifies a disorder and shows it in human terms, it doesn’t only raise awareness. It converts silence into inquiry, and inquiry into appointment volume.

Behind the scenes, NOCD’s CEO of strategy, Stephen Smith, built the company for people like himself. The source says Smith started the company 11 years ago after a severe OCD onset the summer after his sophomore year as a college football player at a small school in South Texas. He went from starting quarterback to housebound in six months, and he says he was misdiagnosed six times before finding a specialist. That specialist charged $400 an hour, cash only, with a seven-month waitlist, but it was “the only chance to get better.” Smith got through it, transferred to Pomona College, finished his degree, and started building NOCD while still going to class and playing football.

That “misdiagnosed six different times” part is not just a personal hardship detail. It’s a lens on why insurance access and training scale matter so much. If the standard path fails repeatedly, then the value proposition shifts from “therapy exists” to “the right therapy exists, reliably, at the right time, and at the right expertise level.” NOCD’s reported insurance reach, plus its therapist training pipeline, is how it aims to turn a historically chaotic care journey into a repeatable system.

Then came the expansion move. This past January, NOCD announced its acquisition of Rebound Health, a PTSD-focused platform, launching a parent brand called Noto, named after AI-powered software that has fueled its growth. The second-order effect here is that the platform is positioning itself to treat overlapping patient needs: OCD and PTSD, and the subset requiring prolonged exposure therapy. For decision-makers, that is a classic platform strategy: deepen the core, then broaden into adjacent indications without forcing a full restart of the operational engine.

Finally, the cultural and communications stakes remain very real. Mandel frames the purpose of talking as opening the door for others to realize they are not alone: platforms that help people name what they experience can reduce stigma and speed up care-seeking. His own description is personal, but it lands as a business principle: diagnosis language is a conversion tool. And for executives watching this space, NOCD’s trajectory suggests the winning mental health companies are not only building tech or running marketing. They are building expertise networks, insurance-compatible delivery at scale, and a care roadmap that can expand as the evidence and demand evolve.